Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023-Reference-Cited by-同舟云学术

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Published:2023-08-25 Issue:34 Volume:72 Page:920-925
ISSN:0149-2195
Container-title:MMWR. Morbidity and Mortality Weekly Report
language:
Short-container-title:MMWR Morb. Mortal. Wkly. Rep.

Author:

Jones Jefferson M.,Fleming-Dutra Katherine E.,Prill Mila M.,Roper Lauren E.,Brooks Oliver,Sánchez Pablo J.,Kotton Camille N.,Mahon Barbara E.,Meyer Sarah,Long Sarah S.,McMorrow Meredith L.

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference28 articles.

1. Food and Drug Administration. Beyfortus (nirsevimab-alip) product label. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf

2. CDC. Grading of recommendations, assessment, development, and evaluation (GRADE): nirsevimab, season 1. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season1-rsv-infants-children.html

3. CDC. Grading of recommendations, assessment, development, and evaluation (GRADE): nirsevimab, season 2. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season2-rsv-infants-children.html

4. CDC. ACIP evidence to recommendations for use of nirsevimab in infants born during RSV season and entering their first RSV vaccine. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season1-rsv-infants-children-etr.html

5. CDC. ACIP evidence to recommendations for use of nirsevimab in children 8–19 months of age with increased risk of severe disease entering their second RSV season. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season2-rsv-infants-children-etr.html

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Poly(A)-Binding Protein Cytoplasmic 1, a tRNA-Derived RNA Fragment-Bound Protein, in Respiratory Syncytial Virus Infection;Pathogens;2024-09-12

2. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments;Pediatrics;2024-09-11

3. Impact of Child Respiratory Syncytial Virus-Confirmed Infections on Caregivers in Japan: A Web-Based Survey;Journal of Clinical Medicine;2024-09-10

4. An evaluation of 2015–2019 United States respiratory syncytial virus hospitalizations as a framework to develop potential strategies for the preventiosn of the hospital burden among infants;eClinicalMedicine;2024-09

5. Infectious Disease Updates for Primary Care;Medical Clinics of North America;2024-09